| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Basic Science Investigation |
1 Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; 2 Institut fur Organische Chemie, Universität Hamburg, Hamburg, Germany; and 3 Department of Radiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts
Correspondence: For correspondence or reprints contact: John V. Frangioni, MD, PhD, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave., Room SL-B05, Boston, MA 02215. E-mail: jfrangio{at}bidmc.harvard.edu
Small-molecule ligands specific for prostate-specific membrane antigen (PSMA) have the potential to improve prostate cancer imaging. However, highly charged ligands are difficult to label with 99mTc and to purify. In this study, we present an adamantane-trimerized small molecule that has nanomolar binding to PSMA and also has 12 negative charges. Methods: To convert this molecule into a clinically viable SPECT diagnostic, we have developed a simple, cartridge-based, solid-phase prelabeling strategy that, within 25 min, converts readily available and inexpensive 99mTc-pertechnetate into a chemically pure complex, with a reactive N-hydroxysuccinimide (NHS) ester, in neat organic solvent. This stable intermediate can label any amine-containing small molecule or peptide with 99mTc in 1 step, with high specific activity and without the need for high-performance liquid chromatography (HPLC). Results: Solid-phase conversion of 99mTc-pertechnetate to 99mTc-MAS3-NHS (MAS3 is S-acetylmercaptoacetyltriserine) could be completed in 25 min, with >99% radiochemical purity and with no coligands present. This intermediate was then conjugated to adamantane-trimerized GPI (2[(3-amino-3-carboxypropyl)(hydroxy)(phosphinyl)-methyl]pentane-1,5-dioic acid) in 1 step with >95% yield and no need for HPLC purification. The final molecule bound specifically to living human tumor cells expressing PSMA on their surface. Quantitative comparison was made among GPI monomer, GPI trimer, and their 99mTc-derivatives. Conclusion: Our study describes a simple cartridge-based conversion of 99mTc-pertechnetate to a useful, preloaded NHS ester intermediate that takes only 25 min to prepare and results in >99% radiochemical purity. Using this chemistry, we produced a high-specific-activity, 99mTc-labeled, PSMA-targeted small molecule and demonstrate 
-ray radioscintigraphic imaging of living human prostate cancer cells.
Key Words: 99mTc-pertechnetate • S-acetylmercaptoacetyltriserine (MAS3) • solid-phase chemistry • SPECT • prostate-specific membrane antigen
COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.
Related articles in JNM:
This article has been cited by other articles:
|
|
 |
|
  K. Kesavan, J. Ratliff, E. W. Johnson, W. Dahlberg, J. M. Asara, P. Misra, J. V. Frangioni, and D. B. Jacoby Annexin A2 Is a Molecular Target for TM601, a Peptide with Tumor-targeting and Anti-angiogenic Effects J. Biol. Chem., February 12, 2010; 285(7): 4366 - 4374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. V. Frangioni New Technologies for Human Cancer Imaging J. Clin. Oncol., August 20, 2008; 26(24): 4012 - 4021. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Misra, D. Lebeche, H. Ly, M. Schwarzkopf, G. Diaz, R. J. Hajjar, A. D. Schecter, and J. V. Frangioni Quantitation of CXCR4 Expression in Myocardial Infarction Using 99mTc-Labeled SDF-1{alpha} J. Nucl. Med., June 1, 2008; 49(6): 963 - 969. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
